In Vitro Efficacy Testing Services for Overactive Bladder

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for overactive bladder. Our services enable detailed profiling of candidate compounds targeting key proteins and pathways implicated in bladder function, such as muscarinic acetylcholine receptors. These platforms are tailored to evaluate pharmacological modulation of neurotransmission and smooth muscle contractility, both central to overactive bladder pathophysiology. We support the identification and optimization of compounds that can address urinary urgency, frequency, and incontinence by interrogating relevant molecular targets.

Our in vitro efficacy testing suite includes radioligand binding, label-free biosensor, and fluorescence-based assays to comprehensively assess drug-target interactions and functional responses. These methods are designed to quantify ligand binding affinity, receptor activation, and downstream signaling, providing multi-faceted insights into compound efficacy. By utilizing diverse assay platforms, we offer robust data to support lead selection and optimization.

Displacement of [3H]-N-methylscopolamine: This radioligand binding assay measures the ability of test compounds to displace a labeled antagonist from muscarinic receptors, quantifying binding affinity and selectivity. It is critical for identifying compounds with high receptor specificity relevant to overactive bladder.

Dynamic mass redistribution assay: This label-free biosensor method detects real-time cellular responses to compound treatment, reflecting integrated receptor activation and downstream signaling events. It enables functional assessment of compound efficacy in a physiologically relevant context.

Fluorescent assay: This method utilizes fluorescent probes to monitor receptor activity or intracellular signaling changes upon compound exposure. It offers high-throughput, quantitative analysis of pharmacological effects on target pathways.

We measure key pharmacological parameters such as IC-50 and Ki to determine compound potency and binding affinity. These metrics are essential for ranking lead compounds and guiding structure-activity relationship studies. Reliable quantitative parameters support rational drug design and reduce attrition in later development stages.

IC-50: The concentration of a compound required to inhibit a biological process or binding event by 50%. It is a standard measure of compound potency in functional assays.

Ki: The equilibrium inhibition constant reflecting a compound’s binding affinity for its target. Lower Ki values indicate stronger and more specific target binding, which is crucial for efficacy and selectivity in drug development.

Recommended In Vitro Efficacy Tests

Cholinergic Receptor Muscarinic 1

Cholinergic Receptor Muscarinic 1 (CHRM1) plays a key role in bladder contraction and overactive bladder pathophysiology. Testing CHRM1 binding is crucial for developing selective therapeutics with fewer side effects. Our assay employs [3H]-N-methylscopolamine displacement to assess compound affinity for CHRM1, providing accurate Ki values to guide lead optimization and ensure target specificity in overactive bladder drug development.

Cholinergic Receptor Muscarinic 3

Cholinergic Receptor Muscarinic 3 (M3) mediates bladder contraction and is a key target in overactive bladder drug development. Testing its function and ligand binding is essential for identifying effective inhibitors. Our service uses dynamic mass redistribution, [^3H]-N-methylscopolamine displacement, and fluorescent assays to assess compound activity. Main parameters measured include IC₅₀ (inhibitory potency) and Kᵢ (binding affinity), providing critical data for lead optimization.